Nutrition and Sleep

Sleep Disorders Medicine

Volumn , Issue , 2009, Pages 307-318

  Partinen, Markku ^a,b  

^a Vitalmed Research Centre   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882561697     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7506-7584-0.00023-9     Document Type: Chapter

References (168)

1. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation 2000, World Health Organization, World Health Organization, Geneva.
2. The World Health Report 2002: Reducing Risks, Promoting Healthy Life 2002, World Health Organization, World Health Organization, Geneva.
3. Roberts H. The syndrome of narcolepsy and diabetogenic hyperinsulinism in the American Negro: important clinical, social and public health aspects. J Am Geriatr Soc 1965, 13:852.
4. Earley C.J., Connor J.R., Beard J.L., et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000, 54:1698.
5. Connor J.R., Boyer P.J., Menzies S.L., et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 2003, 61:304.
6. Magistretti P.J., Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond 1999, 354:1155.
7. Petit J-M., Tobler I., Allaman I., et al. Sleep deprivation modulates brain mRNAs encoding genes of glycogen metabolism. Eur J Neurosci 2002, 16:1163.
8. Pascual J.M., Wang D., Hinton V., et al. Brain glucose supply and the syndrome of infantile neuroglycopenia. Arch Neurol 2007, 64:507.
9. Peng L., Gu L., Zhang H., et al. Glutamine as an energy substrate in cultured neurons during glucose deprivation. J Neurosci Res 2007, 85:3480.
10. Hertz L., Zielke H.R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 2004, 27:735.
11. Newman E.A. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci 2003, 26:536.
12. Kiba T. Relationships between the autonomic nervous system, humoral factors and immune functions in the intestine. Digestion 2007, 74:215.
13. McLean P.G., Borman R.A., Lee K. 5-HT in the enteric nervous system: gut function and neuropharmacology. Trends Neurosci 2007, 30:9.
14. Li Z.S., Schmauss C., Cuenca A., et al. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J Neurosci 2006, 26:2798.
15. Korczynski W., Ceregrzyn M., Matyjek R., et al. Central and local (enteric) action of orexins. J Physiol Pharmacol 2006, 57(Suppl 6):17.
16. Gershon M.D. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005, 39(4 Suppl 3):S184.
17. Liu M., Geddis M.S., Wen Y., et al. Expression and function of 5-HT4 receptors in the mouse enteric nervous system. Am J Physiol Gastrointest Liver Physiol 2005, 289:G1148.
18. de Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322.
19. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573.
20. de Lecea L., Jones B.E., Boutrel B., et al. Addiction and arousal: alternative roles of hypothalamic peptides. J Neurosci 2006, 26:10372.
21. Harris G.C., Aston-Jones G. Arousal and reward: a dichotomy in orexin function. Trends Neurosci 2006, 29:571.
22. Tsujino N., Yamanaka A., Ichiki K., et al. Cholecystokinin activates orexin/hypocretin neurons through the cholecystokinin A receptor. J Neurosci 2005, 25:7459.
23. Harris G.C., Wimmer M., Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005, 437:556.
24. Mieda M., Williams S.C., Sinton C.M., et al. Orexin neurons function in an efferent pathway of a food-entrainable circadian oscillator in eliciting food-anticipatory activity and wakefulness. J Neurosci 2004, 24:10493.
25. Lin L., Faraco J., Li R., et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365.
26. Nishino S., Ripley B., Overeem S., et al. Hypocretin (orexin) deficiency in human narcolepsy [Letter] [see comments]. Lancet 2000, 355:39.
27. Mignot E. Sleep, sleep disorders and hypocretin (orexin). Sleep Med 2004, 5(Suppl 1):S2.
28. Hebebrand J., Muller T.D., Holtkamp K., Herpertz-Dahlmann B. The role of leptin in anorexia nervosa: clinical implications. Mol Psychiatry 2007, 12:23.
29. Vgontzas A.N., Bixler E.O., Chrousos G.P. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 2003, 254:32.
30. Yee B.J., Cheung J., Phipps P., et al. Treatment of obesity hypoventilation syndrome and serum leptin. Respiration 2006, 73:209.
31. Lui M., Gershon M.D. Slow excitatory ("5-HT1P"-like) responses of mouse myenteric neurons to 5-HT: mediation by heterodimers of 5-HT1B/1D and Drd2 receptors. Gastroenterology 2005, 128(4 Suppl 2):A87.
32. Weinstock L.B., Fern S.E., Duntley S.P. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy. Dig Dis Sci 2007, 00:000.
33. Myers R.D. Neuroactive peptides: unique phases in research on mammalian brain over three decades. Peptides 1994, 15:367.
34. Dubrovsky B.O. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:169.
35. Strous R.D., Maayan R., Weizman A. The relevance of neurosteroids to clinical psychiatry: from the laboratory to the bedside. Eur Neuropsychopharmacol 2006, 16:155.
36. George O., Vallee M., Le Moal M., Mayo W. Neurosteroids and cholinergic systems: implications for sleep and cognitive processes and potential role of age-related changes. Psychopharmacology (Berl) 2006, 186:402.
37. McGrath J., Feron F., Eyles D., Mackay-Sim A. Vitamin D: the neglected neurosteroid?. Trends Neurosci 2001, 24:570.
38. Pinna G., Costa E., Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology (Berl) 2006, 186:362.
39. Escudero Alvarez E., Gonzalez Sanchez P. Dietary fibre. Nutr Hosp 2006, 21(Suppl 2):60.
40. Key T.J., Appleby P.N., Rosell M.S. Health effects of vegetarian and vegan diets. Proc Nutr Soc 2006, 65:35.
41. Mattson M.P., Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci 2006, 29:632.
42. Calabrese E.J., Baldwin L.A. Defining hormesis. Hum Exp Toxicol 2002, 21:91.
43. Anghelescu I.G., Kohnen R., Szegedi A., et al. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. Pharmacopsychiatry 2006, 39:213.
44. Clement K., Covertson C.R., Johnson M.J., Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006, 20:197.
45. Kasper S., Anghelescu I.G., Szegedi A., et al. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298]. BMC Med 2006, 4:14.
46. Gastpar M., Singer A., Zeller K. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 2006, 39:66.
47. Fava M., Alpert J., Nierenberg A.A., et al. A Double blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 2005, 25:441.
48. Linde K., Mulrow C.D., Berner M., Egger M. St John's wort for depression. Cochrane Database Syst Rev 2005, 2:CD000448.
49. Mennini T., Gobbi M. The antidepressant mechanism of Hypericum perforatum. Life Sci 2004, 75:1021.
50. Edwards S.J., Montgomery I.M., Colquhoun E.Q., et al. Spicy meal disturbs sleep: an effect of thermoregulation. Int J Psychophysiol 1992, 13:97.
51. Fisone G., Borgkvist A., Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 2004, 61:857.
52. Huang Z.L., Qu W.M., Eguchi N., et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005, 8:858.
53. Porkka-Heiskanen T. Adenosine in sleep and wakefulness. Ann Med 1999, 31:125.
54. Curatolo P.W., Robertson D. The health consequences of caffeine. Ann Intern Med 1983, 98(5 Pt 1):641.
55. Hauri P., Linde S. No More Sleepless Nights 1990, Wiley, New York.
56. Brown S.L., Salive M.E., Pahor M., et al. Occult caffeine as a source of sleep problems in an older population. J Am Geriatr Soc 1995, 43:860.
57. Brice C.F., Smith A.P. Factors associated with caffeine consumption. Int J Food Sci Nutr 2002, 53:55.
58. Landolt H.P., Werth E., Borbely A.A., Dijk D.J. Caffeine intake (200 mg) in the morning affects human sleep and EEG power spectra at night. Brain Res 1995, 675:67.
59. Missak S.S. Does the human body produce a substance similar to caffeine?. Med Hypotheses 1987, 24:161.
60. Kaasinen V., Aalto S., Nagren K., Rinne J.O. Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 2004, 15:281.
61. Belloc N., Breslow L. Relationship of physical health status and health practices. Prev Med 1972, 1:409.
62. Montana V., Ni Y., Sunjara V., et al. Vesicular glutamate transporter-dependent glutamate release from astrocytes. J Neurosci 2004, 24:2633.
63. Zhang Q., Fukuda M., Van Bockstaele E., et al. Synaptotagmin IV regulates glial glutamate release. Proc Natl Acad Sci U S A 2004, 101:9441.
64. Aubert A., Costalat R., Magistretti P.J., Pellerin L. Brain lactate kinetics: modeling evidence for neuronal lactate uptake upon activation. Proc Natl Acad Sci U S A 2005, 102:16448.
65. Spring B., Maller O., Wurtman J., et al. Effects of protein and carbohydrate meals on mood and performance: interactions with sex and age. J Psychiatr Res 1982, 17:155.
66. Spring B., Chiodo J., Harden M., et al. Psychobiological effects of carbohydrates. J Clin Psychiatry 1989, 50(Suppl):27. discussion 34.
67. Christensen L., Redig C. Effect of meal composition on mood. Behav Neurosci 1993, 107:346.
68. Närvänen S. Role of 5-hydroxytryptamine (serotonin) in oral glucose intolerance. Scand J Clin Lab Invest 1983, 167(Suppl):1.
69. Cunliffe A., Obeid O.A., Powell-Tuck J. Post-prandial changes in measures of fatigue: effect of a mixed or a pure carbohydrate or pure fat meal. Eur J Clin Nutr 1997, 51:831.
70. Orr W.C., Shadid G., Harnish M.J., Elsenbruch S. Meal composition and its effect on postprandial sleepiness. Physiol Behav 1997, 62:709.
71. Wells A.S., Read N.W., Uvnas-Moberg K., Alster P. Influences of fat and carbohydrate on postprandial sleepiness, mood, and hormones. Physiol Behav 1997, 61:679.
72. Afaghi A., O'Connor H., Chow C.M. High-glycemic-index carbohydrate meals shorten sleep onset. Am J Clin Nutr 2007, 85:426.
73. Bell I. Diet histories in narcolepsy. Narcolepsy 1975, 221. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
74. Pijl H., Koppeschaar H.P., Cohen A.F., et al. Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans. Int J Obes Relat Metab Disord 1993, 17:513.
75. Winick M. Editorial: Understanding and treating obesity. Am J Publ Health 1996, 86:925.
76. Karacan I., Rosenbloom A., Londono J. The effect of acute fasting on sleep and the sleep growth hormone response. Psychosomatics 1973, 14:33.
77. MacFadyen U.M., Oswald I., Lewis S.A. Starvation and human slow-wave sleep. J Appl Physiol 1973, 35:391.
78. Horne J. Sleep function, with particular reference to sleep deprivation. Ann Clin Res 1985, 17:199.
79. Bonnet M.H., Arand D.L. Metabolic rate and the restorative function of sleep. Physiol Behav 1996, 59:777.
80. Spiegel K., Leproult R., Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999, 354:1435.
81. Hyun D.H., Emerson S.S., Jo D.G., et al. Calorie restriction up-regulates the plasma membrane redox system in brain cells and suppresses oxidative stress during aging. Proc Natl Acad Sci U S A 2006, 103:19908.
82. Roky R., Chapotot F., Hakkou F., et al. Sleep during Ramadan intermittent fasting. J Sleep Res 2001, 10:319.
83. Magistretti P.J. Brain energy metabolism. Fundamental Neuroscience 2003, 339. Elsevier Academic, Amsterdam. 2nd ed. L.R. Squire, F.E. Bloom, S.K. McConnell (Eds.).
84. Hallbook T., Lundgren J., Rosen I. Ketogenic diet improves sleep quality in children with therapy-resistant epilepsy. Epilepsia 2007, 48:59.
85. Brown A.J. Low-carb diets, fasting and euphoria: is there a link between ketosis and gamma-hydroxybutyrate (GHB)?. Med Hypotheses 2007, 68:268.
86. Bonnet M.H., Gomez S., Wirth O., Arand D.L. The use of caffeine versus prophylactic naps in sustained performance. Sleep 1995, 18:97.
87. Horne J.A., Reyner L.A. Counteracting driver sleepiness: effects of napping, caffeine, and placebo. Psychophysiology 1996, 33:306.
88. Reyner L.A., Horne J.A. Suppression of sleepiness in drivers: combination of caffeine with a short nap. Psychophysiology 1997, 34:721.
89. Hays J.C., Blazer D.G., Foley D.J. Risk of napping: excessive daytime sleepiness and mortality in an older community population. J Am Geriatr Soc 1996, 44:693.
90. Naska A., Oikonomou E., Trichopoulou A., et al. Siesta in healthy adults and coronary mortality in the general population. Arch Intern Med 2007, 167:296.
91. Taasan V., Block A., Boysen P., et al. Alcohol increases sleep apnea and oxygen saturation in asymptomatic men. Am J Med 1981, 71:240.
92. Issa F., Sullivan C. Alcohol, snoring and sleep apnea. J Neurol Neurosurg Psychiatry 1982, 45:353.
93. Remmers J. Obstructive sleep apnea: a common disorder exacerbated by alcohol. Am Rev Respir Dis 1984, 130:153.
94. Vitiello M., Prinz P., Personius J., et al. History of chronic alcohol abuse is associated with increased night time hypoxemia in older men. Alcoholism 1987, 11:368.
95. Mitler M., Dawson A., Henriksen S., et al. Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. Alcoholism 1988, 12:801.
96. Bloom J., Kaltenborn W., Quan S. Risk factors in a general population for snoring: importance of cigarette smoking and obesity. Chest 1988, 93:678.
97. Stradling J.R., Crosby J.H. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax 1991, 46:85.
98. Phillips B.A., Danner F.J. Cigarette smoking and sleep disturbance. Arch Intern Med 1995, 155:734.
99. Nieto F.J., Young T.B., Lind B.K., et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000, 283:1829.
100. O'Brien P.E., Dixon J.B. The extent of the problem of obesity. Am J Surg 2002, 184(Suppl 6b):S4.
101. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002, 165:1217.
102. National Hebrew Medical Research Center. Physical illness in alcoholism.
103. Palmer C.D., Harrison G.A., Hiorns R.W. Association between smoking and drinking and sleep duration. Ann Hum Biol 1980, 7:103.
104. Williams G.D., Grant B.F., Stinson F.S., et al. Trends in alcohol related morbidity and mortality. Public Health Rep 1988, 103:592.
105. Houyez F., Degoulet P., Cittee J., et al. Sleep and hypertension: an epidemiologic study in 7,901 workers. Arch Mal Coeur Vaiss 1990, 83:1085.
106. Mun E.C., Blackburn G.L., Matthews J.B. Current status of medical and surgical therapy for obesity [Review]. Gastroenterology 2001, 120:669.
107. Adams P.F., Schoenborn C.A. Health behaviors of adults: United States, 2002-04. Vital Health Stat 2006, 10(230):1.
108. Kohatsu N.D., Tsai R., Young T., et al. Sleep duration and body mass index in a rural population. Arch Intern Med 2006, 166:1701.
109. Schneider D.L. Insomnia: safe and effective therapy for sleep problems in the older patient. Geriatrics 2002, 57:24, 29, 32.
110. Bearpark H., Elliott L., Grunstein R., et al. Occurrence and correlates of sleep disordered breathing in the Australian town of Busselton: a preliminary analysis. Sleep 1993, 16(8 Suppl):S3.
111. Roth T., Roehrs T., Zorick F., Conway W. Pharmacological effects of sedative-hypnotics, narcotic analgesics, and alcohol during sleep. Med Clin North Am 1985, 69:1281.
112. Urponen H., Vuori I., Hasan J., Partinen M. Self-evaluations of factors promoting and disturbing sleep: an epidemiological survey in Finland. Soc Sci Med 1988, 26:443.
113. Lobo L.L., Tufik S. Effects of alcohol on sleep parameters of sleep-deprived healthy volunteers. Sleep 1997, 20:52.
114. Pressman M.R. Factors that predispose, prime and precipitate NREM parasomnias in adults: clinical and forensic implications. Sleep Med Rev 2007, 11(5):31. discussion.
115. Gross M., Hastey J. A note of REM rebound during experimental alcohol withdrawal in alcoholics. Adv Exp Med Biol 1975, 59:509.
116. Williams D., MacLean A., Cairns J. Dose-response effects of ethanol on the sleep of young women. J Stud Alcohol 1983, 44:515.
117. Yules R., Freedman D., Chandler K. The effect of ethyl alcohol on man's electroencephalographic sleep cycle. Electroenceph Clin Neurophysiol 1966, 20:109.
118. Adamson J., Burdick J. Sleep of dry alcoholics. Arch Gen Psychiatry 1973, 28:146.
119. Mishara B.L., Kastenbaum R. Wine in the treatment of long-term geriatric patients in mental institutions. J Am Geriatr Soc 1974, 22:88.
120. Kripke D., Garfinkel L. Excess nocturnal deaths related to sleeping pill and tranquilliser use. Lancet 1984, 1:99.
121. Pollak C., Perlick D., Linsner J., et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health 1990, 15:123.
122. Rumble R., Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc 1992, 40:787.
123. Morgan K., Clarke D. Longitudinal trends in late-life insomnia: implications for prescribing. Age Ageing 1997, 26:179.
124. Kripke D.F., Klauber M.R., Wingard D.L., et al. Mortality hazard associated with prescription hypnotics. Biol Psychiatry 1998, 43:687.
125. Kojima M., Wakai K., Kawamura T., et al. Sleep patterns and total mortality: a 12-year follow-up study in Japan. J Epidemiol 2000, 10:87.
126. Phillips B., Mannino D.M. Does insomnia kill?. Sleep 2005, 28:965.
127. Carroll P.J. The social hour for geropsychiatric patients. J Am Geriatr Soc 1978, 26:32.
128. Holman R.T. The slow discovery of the importance of omega 3 essential fatty acids in human health. J Nutr 1998, 128(2 Suppl):427s.
129. Chiu C-C., Huang S-Y., Shen Winston W., Su K-P. Omega-3 fatty acids for depression in pregnancy. Am J Psychiatry 2003, 160:385.
130. Haag M. Essential fatty acids and the brain. Can J Psychiatry 2003, 48:195.
131. Horrocks L.A., Yeo Y.K. Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 1999, 40:211.
132. Din J.N., Newby D.E., Flapan A.D. Omega 3 fatty acids and cardiovascular diseasefishing for a natural treatment. BMJ 2004, 328:30.
133. Mazza M., Pomponi M., Janiri L., et al. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:12.
134. Antalis C.J., Stevens L.J., Campbell M., et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2006, 75:299.
135. Freeman M.P., Hibbeln J.R., Wisner K.L., et al. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954.
136. Portwood M.M. The role of dietary fatty acids in children's behaviour and learning. Nutr Health 2006, 18:233.
137. Richardson A.J. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006, 18:155.
138. Williams A.L., Katz D., Ali A., et al. Do essential fatty acids have a role in the treatment of depression?. J Affect Disord 2006, 93:117.
139. Lim W.S., Gammack J.K., Van Niekerk J., Dangour A.D. Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev 2006, 1:CD005379.
140. Weinstock-Guttman B., Baier M., Park Y., et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids 2005, 73:397.
141. Wingerchuk D.M., Benarroch E.E., O'Brien P.C., et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005, 64:1267.
142. Schachter H.M., Kourad K., Merali Z., et al. Effects of omega-3 fatty acids on mental health. Evid Rep Technol Assess (Summ) 2005, 116:1.
143. Hibbeln J.R., Makino K.K., Martin C.E., et al. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry 2003, 53:431.
144. Zanarini M.C., Frankenburg F.R. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003, 160:167.
145. Stevens L.J., Zentall S.S., Abate M.L., et al. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav 1996, 59:915.
146. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885.
147. Lee S., Gura K.M., Kim S., et al. Current clinical applications of omega-6 and omega-3 fatty acids. Nutr Clin Pract 2006, 21:323.
148. Fenton W.S., Dickerson F., Boronow J., et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001, 158:2071.
149. Balk E.M., Lichtenstein A.H., Chung M., et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006, 189:19.
150. Rao J.S., Ertley R.N., Lee H.J., et al. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol Psychiatry 2007, 12:36.
151. Fagioli I., Baroncini P., Ricour C., Salzarulo P. Decrease of slow-wave sleep in children with prolonged absence of essential lipids intake. Sleep 1989, 12:495.
152. Cheruku S.R., Montgomery-Downs H.E., Farkas S.L., et al. Higher maternal plasma docosahexaenoic acid during pregnancy is associated with more mature neonatal sleep-state patterning. Am J Clin Nutr 2002, 76:608.
153. Bruck D., Armstrong S., Coleman G. Sleepiness after glucose in narcolepsy. J Sleep Res 1994, 3:171.
154. Roth B., Nevsimalova S., Sonka K., Docekal P. An alternative to the Multiple Sleep Latency Test for determining sleepiness in narcolepsy and hypersomnia: polygraphic score of sleepiness. Sleep 1986, 9:243.
155. Husain A.M., Yancy W.S., Carwile S.T., et al. Diet therapy for narcolepsy. Neurology 2004, 62:2300.
156. Chabas D., Foulon C., Gonzalez J., et al. Eating disorder and metabolism in narcoleptic patients. Sleep 2007, 30:1267.
157. Nordlander S.B. Intravenous iron in treatment of restless legs. Acta Med Scand 1953, 145:453.
158. Sun E.R., Chen C.A., Ho G., et al. Iron and the restless legs syndrome. Sleep 1998, 21:371.
159. Earley C.J., Heckler D., Allen R.P. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004, 5:231.
160. Sloand J.A., Shelly M.A., Feigin A., et al. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 2004, 43:663.
161. Earley C.J., Heckler D., Allen R.P. Repeated IV doses of iron provide effective supplemental treatment of restless legs syndrome. Sleep Med 2005, 6:301.
162. Yehuda S., Yehuda M. Long lasting effects of infancy iron deficiencypreliminary results. J Neural Transm Suppl 2006, 71:197.
163. Dosman C.F., Brian J.A., Drmic I.E., et al. Children with autism: effect of iron supplementation on sleep and ferritin. Pediatr Neurol 2007, 36:152.
164. Kuhn E., Brodan V. Changes in the circadian rhythm of serum iron induced by a 5-day sleep deprivation. Eur J Appl Physiol Occup Physiol 1982, 49:215.
165. Winick M. Nutrition and brain development. Curr Concepts Nutr 1984, 13:71.
166. Morgane P.J., Austin-LaFrance R., Bronzino J., et al. Prenatal malnutrition and development of the brain. Neurosci Biobehav Rev 1993, 17:91.
167. Guardiola A., Fuchs F.D., Terra A.R., et al. [Importance of nutritional aspects in attention deficit hyperactivity disorders]. Arq Neuropsiquiatr 1997, 55:598.
168. Fernstrom J.D. Can nutrient supplements modify brain function. Am J Clin Nutr 2000, 7(Suppl 1):1669S.